Skip to content
Menu

ZIVO Bioscience, Inc. ZIVO

Full chart Compare
Set alert

Price alert · ZIVO

All alert types
5.50 USD -0.25 (-4.35%)

As ofNov 16, 2026, 1:23 PM EST

5.50 Day range 5.99
1.11 52-week range 12.04
YTD
-36.78%
1 year
-55.10%

Fundamental scorecard

1 of 25 checks passed on ZIVO’s reported financials

ValueGrowthProfitabilityHealthDividend

1of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2023.

Value 0 of 5

  • Failed:P/E below its own 5-year median No profit over the last 12 months, so no P/E.
  • Failed:P/E under 20 No profit over the last 12 months, so no P/E.
  • No data:Price to sales below its own 5-year median Price to sales 1463. Not enough data to decide.
  • Failed:Price to book below its own 5-year median Shareholders’ equity is negative.
  • Failed:Free cash flow yield above 4% Free cash flow of -6.53M is -28.2% of the market value.

Growth 0 of 5

  • No data:Revenue grew over the last year Not enough data to decide.
  • No data:Revenue grew more than 5% a year over five years Not enough data to decide.
  • Failed:Earnings per share grew over the last year EPS -5.31 against -5.18 in the 12 months before.
  • Failed:Earnings per share grew more than 5% a year over five years EPS -33.60 in FY 2017, -5.58 in FY 2022.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 0 of 5

  • Failed:Profitable over the last year Net income of -8.51M over the last 12 months.
  • Failed:Profitable in each of the last five fiscal years A profit in 0 of the last 5 fiscal years.
  • Failed:Return on equity above 15% Return on equity of -3956.0%.
  • No data:Net margin above its 5-year average Not enough data to decide.
  • Failed:Free cash flow is at least 80% of net income No profit over the last 12 months to compare with.

Financial health 1 of 5

  • Failed:Short-term assets cover short-term liabilities Short-term assets of 1.95M against short-term liabilities of 3.17M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 1.95M against long-term liabilities of 22.0K.
  • Failed:Net debt under 40% of equity Shareholders’ equity is negative.
  • Failed:Operating cash flow covers at least 20% of debt Operating cash flow of -6.53M is -434.8% of debt.
  • Failed:Operating profit covers interest at least 3 times Operating profit is -119.7 times the interest expense.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Financial position

What ZIVO owns and owes, as of Sep 30, 2023

Short term and long term

Balance sheet · 2.10M of assets

Liabilities exceed assets, so there is no shareholders’ equity to show.

Debt, equity and cash by year

Now: 17.5K of debt after cash

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Cash flow and returns

How ZIVO’s profit turns into cash, and what its capital earns

From profit to free cash flow · Last 12 months

Returns on capital · Last 12 months

  • -3956.0%

    Return on equity

    Below the 15% mark · Profit per dollar of shareholders’ equity

  • -280.2%

    Return on assets

    Below the 5% mark · Profit per dollar of everything it owns

From the company’s SEC filings. The tick on each dial is a common rule-of-thumb level, not a target.

Financial health

Altman Z-Score

-514.50 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

2 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

C2 / 5 overall

  • DCF 1
  • Return on Equity 5
  • Return on Assets 1
  • Debt / Equity 1
  • P/E 1
  • P/B 1

Valuation

P/E -3.4×
P/S 279×
P/B -8.9×
P/FCF -10.1×
EV/EBITDA -3.4×
EV/Sales 284×
FCF Yield -9.9%

Profitability

Gross Margin 33.6%
Operating Margin -8278.8%
Net Margin -8311.1%
ROE 263.9%
ROIC 316.8%
ROA -1490.7%

Growth (YoY)

Revenue -24.3%
Operating Income 26.3%
EPS (diluted) 33.9%
Free Cash Flow 23.8%

Financial Health

Current Ratio 0.1×
Quick Ratio 0.0×
Debt / Equity -0.2×
Net Debt / EBITDA -0.1×
Interest Coverage -284×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31